Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Surgeon General Links Obesity to Cancer

February 1, 2002
Publication
Article
OncologyONCOLOGY Vol 16 No 2
Volume 16
Issue 2

A recent report on obesity released by US Surgeon General Dr. David Satcher said that about 300,000 people in the United States die each year from diseases related directly to being overweight, including heart disease and cancer.

A recent report on obesity released by US SurgeonGeneral Dr. David Satcher said that about 300,000 people in the United Statesdie each year from diseases related directly to being overweight, includingheart disease and cancer. 

The report, entitled "The Surgeon General’sCall to Action to Prevent and Decrease Overweight and Obesity," outlinedstrategies that communities can use in helping to address the problem. Thoseoptions include requiring physical education at all school grades, providingmore healthy food options on school campuses, and providing safe and accessiblerecreational facilities for residents of all ages. The report links beingoverweight or obese with an increased risk for some types of cancer includingendometrial, colon, gall bladder, prostate, kidney, and postmenopausal breastcancer. Women gaining more than 20 lb from age 18 to midlife double their riskof postmenopausal breast cancer, compared to women whose weight remains stable.

Articles in this issue

Surgeon General Links Obesity to Cancer
Medicare Delays New Outpatient Payment System
New Report on Nation’s Progress Against Cancer Released
Atlas of Breast Cancer, Second Edition
Subcutaneous Amifostine May Be as Effective as Intravenous Administration
Newly Designated NCI Director Roundly Applauded by Cancer Community
Stress Accelerates AIDS Progression, Undermines the Effect of Therapy
Association of Community Cancer Centers Launches New Public Policy Website
Radioimmunotherapy Improves Response in Chemotherapy-Refractory NHL
Novel Chemoradiation Regimen Improves Outlook in Early-Stage Hodgkin’s Disease
Ineffective Cancer Pain Management Analyzed
Cancer Vaccines and Immunotherapy
Commentary (Gilbert): Carcinomatous Meningitis: It Does Not Have to Be a Death Sentence
Clinical Trials and NCI Resources for Cancer in HIV-Positive Patients
Current Status of Genetic Testing for Colorectal Cancer Susceptibility
Recent Videos
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
The use of enhanced imaging and adaptive radiotherapy has lessened the burden on patients with cancer receiving radiotherapy as treatment.
7 experts are featured in this series.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Related Content
Advertisement

•	Nivolumab plus ipilimumab continued to show clinically meaningful PFS improvement over nivolumab alone in MSI-H/dMMR mCRC.

Nivolumab/Ipilimumab Maintain PFS Benefit vs Nivolumab Monotherapy in MSI-H/dMMR CRC

Kristie L. Kahl
October 20th 2025
Article

With a median follow-up of 50.1 months, nivolumab plus ipilimumab achieved a median PFS of not reached compared with 60.8 months with nivolumab monotherapy in this CRC population.


“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.


The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Camrelizumab/Famitinib Show First-Line PFS Benefit in Cervical Cancer

Kyle Doherty
October 20th 2025
Article

The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Site Logo

Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma

Alex Biese
October 20th 2025
Article

A novel cancer vaccine, IO102-IO103, combined with pembrolizumab, showed promising results in improving PFS for advanced melanoma.


Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E-mutated non–small cell lung cancer.

Frontline Immunotherapy Improves OS Vs BRAF/MEK Inhibitors in BRAF+ NSCLC

Russ Conroy
October 20th 2025
Article

Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E-mutated non–small cell lung cancer.

Related Content
Advertisement

•	Nivolumab plus ipilimumab continued to show clinically meaningful PFS improvement over nivolumab alone in MSI-H/dMMR mCRC.

Nivolumab/Ipilimumab Maintain PFS Benefit vs Nivolumab Monotherapy in MSI-H/dMMR CRC

Kristie L. Kahl
October 20th 2025
Article

With a median follow-up of 50.1 months, nivolumab plus ipilimumab achieved a median PFS of not reached compared with 60.8 months with nivolumab monotherapy in this CRC population.


“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.


The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Camrelizumab/Famitinib Show First-Line PFS Benefit in Cervical Cancer

Kyle Doherty
October 20th 2025
Article

The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Site Logo

Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma

Alex Biese
October 20th 2025
Article

A novel cancer vaccine, IO102-IO103, combined with pembrolizumab, showed promising results in improving PFS for advanced melanoma.


Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E-mutated non–small cell lung cancer.

Frontline Immunotherapy Improves OS Vs BRAF/MEK Inhibitors in BRAF+ NSCLC

Russ Conroy
October 20th 2025
Article

Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E-mutated non–small cell lung cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.